Last Updated: 13 Nov 2024
Executive Summary
TG Therapeutics Inc. (TGTX) is a commercial-stage biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases. The company has a market capitalization of $4.78 billion and trades on the NASDAQ exchange.
Company Overview
TG Therapeutics' lead product is Ublituximab, a monoclonal antibody approved for the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The company also has a pipeline of other candidates in development, including TG-1701, a novel PI3K delta inhibitor for the treatment of hematologic malignancies, and TG-1501, an anti-CD20 antibody for the treatment of non-Hodgkin lymphoma.
Fundamental Analysis
TG Therapeutics reported revenue of $264.79 million for the trailing twelve months, a decrease of 0.49% year-over-year. The company's gross profit margin is 0.95%, and its operating margin is 14.8%. TG Therapeutics is not yet profitable, with a net loss of $408 million for the trailing twelve months.
The company's balance sheet is strong, with $1.34 billion in cash and equivalents and no debt. TG Therapeutics has a book value of $1.34 per share.
Technical Analysis
TG Therapeutics' stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages. The relative strength index (RSI) is 62.6, indicating that the stock is overbought.
Short Term Outlook
The technical analysis suggests that TG Therapeutics' stock is overbought and could be due for a correction. However, the company's strong fundamentals and positive analyst sentiment suggest that the stock could continue to perform well in the long term.
Long Term Outlook
TG Therapeutics is a promising biopharmaceutical company with a strong pipeline of novel treatments. The company's lead product, Ublituximab, has shown promising results in clinical trials and is expected to be a major driver of growth in the coming years. The company's other candidates in development also have the potential to be successful.
Analyst Recommendations
Analysts are generally positive on TG Therapeutics. The consensus analyst rating is "buy," with an average target price of $38.13. Two analysts rate the stock as a "strong buy," five rate it as a "buy," one rates it as a "hold," and one rates it as a "sell."
